Acadia is having another go at Nuplazid (pimavanserin), hoping to convince the FDA’s Psychopharmacologic Drugs Advisory Committee that the antipsychotic should win a new indication as a treatment for dementia-related hallucinations and delusions.
Source: Drug Industry Daily